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Supplementary Note 1 
 
We obtained additional information for two other unrelated individuals who possessed a T787A mutation.  
Individual 3 was an adolescent found to have intractable epilepsy. Individual 3 was diagnosed with Lennox-
Gastaut syndrome without status epilepticus.  Individual 4 was an adult diagnosed with intractable migraine 
accompanied by localization-related epilepsy with complex partial seizures. In both cases, the T787A mutation 
was identified through a complete epilepsy panel, and we could only obtain limited phenotypic information about 
these individuals.  Importantly, the parental origin of the mutation was not established in either individual. We 
also identified another mutation at this site (T787M) that raised UBE3A activity 795.38% ± 101.8 above WT levels 
(Table 1), but we were not able to obtain phenotypic information for this individual.   
Individual 8 was a child who possessed a L781H mutation that increased UBE3A activity 615.29% ± 72.7 
above WT levels (Supplementary Data 1). The proband had a low APGAR score at birth with good recovery, 
and no prenatal, pregnancy, or delivery issues. There was no family history of neurodevelopmental disease. 
Individual 8 was diagnosed initially with developmental delay with hypotonia, feeding issues, and 
gastroesophageal reflex disease. The individual’s functional age was determined to be 15-18 months at the time 
of examination, and the individual displayed minimal dysmorphism and normal pre and postnatal growth. 
Epilepsy was observed during infancy and consisted of daily events of behavior arrest, staring, and lip smacking, 
with occasional eye deviation. Tremulousness in the upper extremities was evident in childhood. Individual 7 
exhibited autistic phenotypes including mild sensory issues with light, echolalia, and head banging, but these 
phenotypes were not consistent with Angelman syndrome. Sequencing confirmed that the L781H mutation was 
on the maternally-inherited allele. Individual 8 exhibited unusual levels of fatigue and subsequent metabolic 
studies indicated some mitochondrial dysfunction. Additional sequencing also identified a pathogenic variant in 
STXBP1. 
We obtained limited information for Individual 9. The proband possessed an A521T mutation that 
increased UBE3A activity 464.25% ± 40.0 above WT levels (Supplementary Data 1). The patient exhibited 
seizures and developmental delay. Sequencing analysis confirmed the mutation was maternally inherited. The 
mother was unaffected, but had a family history of seizures, suggesting she may have been a carrier for the 
mutation.  
Finally, we identified two additional cases in which the parental origin could not be established. Individual 
10 was an adolescent who possessed a R516W mutation that raised activity 812.28% ± 43.8 above WT UBE3A 
levels. The proband presented with feeding difficulties and began to exhibit staring spells as a child.  Individual 
10 was diagnosed initially with fetal alcohol syndrome. As a child, the patient’s staring spells became frequent 
and abnormal EEG patterns were evident. The proband failed six different drug treatments to control seizures, 
and complex seizures including atonic and tonic/clonic seizures were present in childhood. Consistent cognitive 
delays were also noted without evidence of regression. The proband was not tested for autism due to the extent 
of the individual’s intellectual disability. MRI studies showed that Individual 10 possessed a small right choroidal 
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tissue cyst and moderate skeletal deformations including mild tibial torsion. Individual 10 was adopted and the 
parental origin of the UBE3A mutation could not be established.  Notably, our screen also identified an additional 
mutation at this site (R516Q) that increased activity 288.95% ± 11.1 above WT enzyme levels. Individual 11 was 
a child who possessed a G755S mutation that raised UBE3A activity 177.36% ± 12.5 above WT enzyme levels. 
This individual exhibited seizures and developmental delay. Sequencing analysis determined the mother was 
negative for the mutation, but it was unknown if the mutation was paternally inherited or de novo. Collectively, 
these data demonstrate that hyperactivating mutations in UBE3A are sufficient to cause a distinct disorder that 












Supplementary Figure 1: Additional characterization of UBE3A variants. 
(a) Concordant (gray) and Discordant (black) determinations between functional and in silico characterization of 
UBE3A variants tested in this study. 
 
(b) Comprehensive mutational analysis at amino acid positions 781 and 787 in UBE3A.  Heat plots show mean 
responses of mutants in the BAR assay.  White shading represents WT UBE3A activity levels, blue shading 
indicates loss-of-function, and red shading indicates gain-of-function. Scale bar shows the percent change 
relative to WT UBE3A. *p<0.05, **p<0.005, p<0.0005, One-sample t-test (two-tailed) with Benjamini-Hochberg 












Supplementary Figure 2: Characterization of hyperactive UBE3A mutations. 
(a and b) Representative western blot and quantification of HEK293T cells transfected with the indicated 
constructs.  Values are shown as the average percent of WT UBE3A levels ± SE.  N = 3 independent 
experiments, T485A, *p = 0.016; R516W, *p = 0.0063; A521T, p = 0.012; Q588E, *p = 0.009; L781H, *p = 0.0014; 
T787A, p = 0.03, One-sample t-test (two-tailed) with Bonferroni multiple comparisons correction. 
 
(c) HEK293T cells transfected with the indicated Myc-UBE3A and FLAG-ubiquitin constructs were treated with 
the proteasome inhibitor MG-132 (30 µM, 1 hr).  UBE3A was immunoprecipitated using an anti-Myc antibody 
and probed by western blot with an anti-FLAG antibody to detect ubiquitinated UBE3A.  Representative images 
are shown from three independent experiments that produced similar results. 
 
(d and e) HEK293T cells were transfected with the indicated Myc-tagged UBE3A constructs and FLAG-tagged 
RING1B.  Protein levels for RING1B were monitored by western blot.  Quantification is shown in (e).  Values are 
shown as the mean percent ± SE of WT UBE3A expressing cells, n = 3 independent experiments, No UBE3A, 
*p = 0.018; UBE3A LD, *p = 0.011; R516Q, *p = 0.027; R516W, *p = 0.029; A521T, *p = 0.022; Q588E, *p = 
0.027; L781H, *p = 0.014; T787A, *p = 0.044; T787M, *p = 0.021, One-sample t-test (two-tailed) with Bonferroni 










Supplementary Figure 3: UBE3A possesses a degenerate exosite. 
(a) The NEDD4 HECT domain (gray) co-crystallized with ubiquitin (pink).  Boxed areas show primary contact 
points consisting of I44 of ubiquitin with F707 of NEDD4, and L73 of ubiquitin with Y605 and Y634 of NEDD4. 
 
(b) Sequence alignment showing the conservation of putative ubiquitin contacting residues (green circles) in 
UBE3A. Residues highlighted in yellow are critical for the binding of UBE3A to the C-terminus of ubiquitin.  Note 
the high degree of sequence conservation across all species. 
 
(c) Sequence alignment of the exosite of NEDD4 subfamily enzymes with UBE3A.  Ubiquitin-contacting residues 
are marked with green circles.  Mutations (black) and benign variants (gray) characterized in this study are shown 
above the alignment. Residues highlighted in yellow are critical for the binding of NEDD4 sub-family enzymes to 
the C-terminus of ubiquitin. Note the high degree of conservation of ubiquitin contacting residues in NEDD4 
subfamily enzymes and the lack of conservation with UBE3A. 
 
(d) Normalized BAR responses from HEK293T cells transfected with the indicated constructs.  Data are shown 
as the mean ± SE, n = 3 independent experiments, One-sample t-test with Bonferroni multiple comparisons 
correction (FDR = 0.05), GFP, ***p = 1.22 x 10-5; UBE3A LD, ***p = 3.07 x 10-5; F665A, ***p = 1.26 x 10-4. 
 
(e)  Surface charges at Q588 position are altered by mutations tested in this screen.  Positive charges are 











Supplementary Figure 4: Additional disease-linked exosite mutations in HECT domain enzymes. 
 
(a) Sequence alignment showing amino acids that comprise the exosite.  Green circles represent ubiquitin-
contact sites.  Residues highlighted in yellow are critical for binding to the C-terminus of ubiquitin.  Red boxes 
indicate positions containing disease-linked mutations. 
 
(b) Crystal structures showing the positions of mutations (red) within the exosite of indicated HECT domain 
enzymes (gray). 
 










Supplementary Figure 5: The UBE3A Q588E mutation causes neurological deficits in a mouse model.  
 
(a) Mating schemes used to generate heterozygous mice with a maternally-inherited Q588E mutation (mQ588E) 
and a paternally-inherited Q588E mutation (pQ588E). 
  
(b) Western blot analysis showing UBE3A (black arrowhead) and actin (red arrowhead) protein levels in the 
cortex from WT, mQ588E, and pQ588E mice.  Three mice per genotype were analyzed in each blot. 
 
(c) Individual and mean ± SE for righting times for WT (black) and mQ588E (gray) animals in the righting reflex 
assay.  WT, n = 29 animals; mQ588E, n = 14 animals. 
 
(d and e) Grasping reflexes measured for the forepaw and hindpaw of WT (black) and mQ588E (gray) animals.  
Values are shown as the percent of tested animals exhibiting the grasping reflex; n.s., not significant.  WT, n = 
29 animals; mQ588E, n = 16 animals. 
 
(f) Individual and mean ± SE times for WT (black) and mQ588E (gray) mice in the negative geotaxis assay are 
shown.  Each animal was tested three times and the average of the three trials was used for analysis. WT, n = 
29 animals; mQ588E, n = 19 animals.  
 
(g) Pitch frequency from ultrasonic vocalization measured between WT (black) and mQ588E (gray) mice.  Data 
are shown as the mean ± SE, *p = 0.01 at P7, *p = 0.048 at P9, Univariate linear mixed model. WT: P5, n = 28 
animals, P7, n = 27 animals, P9, n = 24 animals; mQ588E, P5, n = 11 animals, P7, n = 23 animals, P9, n = 17 
animals. 
 
(h) Duration of ultrasonic vocalizations measured between WT (black) and mQ588E (gray) mice. Data are shown 
as the mean ± SE, *p = 0.033 at P5, *p = 0.044 at P9, Univariate linear mixed model. WT: P5, n = 28 animals, 
P7, n = 27 animals, P9, n = 24 animals; mQ588E, P5, n = 11 animals, P7, n = 20 animals, P9, n = 14 animals. 
 
(i) Pause duration between ultrasonic vocalizations measured between WT (black) and mQ588E (gray) mice.  
Data are shown as the mean ± SE, ***p = 0.00045, Univariate linear mixed model.  WT: P5, n = 28 animals, P7, 
n = 27 animals, P9, n = 24 animals; mQ588E, P5, n = 11 animals, P7, n = 19 animals, P9, n = 14 animals.   
 
(j) Pitch frequency from ultrasonic vocalization measured between WT (black) and pQ588E (blue) mice.  Data 
are shown as the mean ± SE, *p = 0.033 at P5, Univariate linear mixed model. WT: P5, n = 15 animals, P7, n = 
17 animals, P9, n = 13 animals; pQ588E, P5, n = 23 animals, P7, n = 19 animals, P9, n = 22 animals. 
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(k) Duration of ultrasonic vocalizations measured between WT (black) and pQ588E (blue) mice. Data are shown 
as the mean ± SE. WT: P5, n = 15 animals, P7, n = 17 animals, P9, n = 13 animals; pQ588E, P5, n = 23 animals, 
P7, n = 19 animals, P9, n = 22 animals. 
 
(l) Pause duration between ultrasonic vocalizations measured between WT (black) and pQ588E (blue) mice.  
Data are shown as the mean ± SE.  WT: P5, n = 15 animals, P7, n = 17 animals, P9, n = 13 animals; pQ588E, 
P5, n = 23 animals, P7, n = 19 animals, P9, n = 22 animals.   
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Supplementary Table 1.  Results of comprehensive mutation analysis experiments, related to Figure 2 and 
Figure 5. Data are shown as the percent change from WT UBE3A responses in the BAR assay. All variants were 
tested were tested in 3 independent experiments.  Luciferase responses were normalized to WT UBE3A and p-
values were calculated using a one-sample t-test (two-tailed) with Benjamini-Hochberg multiple comparisons 








Acid Position 588 
Standard 
Error Adjusted P Position 781 
Standard 
Error Adjusted P Position 787 
Standard 
Error Adjusted P 
Q 100   208.33 13.3424 0.01879 87.97 5.2205 0.1651 
N 153.53 6.877 0.306 580.15 26.8470 0.00780 19.98 3.0837 0.0026 
S 112.62 6.504 1 656.55 36.4466 0.00833 51.64 5.0179 0.0155 
T 125.72 10.744 1 300.34 17.6447 0.01206 100.00 0.0000  
E 389.10 76.462 0.002 335.09 15.6175 0.00833 2.23 0.3203 0.0000 
D 320.25 42.140 0.010 363.57 11.1185 0.00674 2.37 0.3693 0.0000 
R 5.60 1.917 0.000 136.22 23.4360 0.27685 3.00 0.9161 0.0000 
K 6.60 1.621 0.006 89.72 17.0064 0.60711 2.99 0.3570 0.0000 
H 12.20 8.907 0.019 308.53 23.9771 0.01759 520.07 49.3264 0.0183 
F 10.76 1.551 0.006 123.40 6.6643 0.08600 108.42 8.0221 0.4038 
Y 5.10 0.557 0.001 84.56 9.2743 0.26581 41.88 4.8457 0.0109 
W 10.42 1.288 0.004 379.07 8.8472 0.00629 8.58 0.4832 0.0001 
L 2.70 1.363 0.004 100.00   46.26 1.7135 0.0019 
V 19.00 1.223 0.004 53.91 4.2129 0.01206 276.32 26.1131 0.0269 
I 25.43 1.549 0.008 52.83 1.7179 0.00629 118.27 8.4108 0.0973 
C 36.64 1.972 0.018 224.72 7.1658 0.00780 1245.07 77.9073 0.0001 
P 2.19 0.313 0.000 7.49 1.3088 0.00380 1.33 0.2941 0.0000 
M 11.09 1.014 0.002 230.89 9.8647 0.00973 795.38 101.7885 0.0002 
G 1.72 0.393 0.000 217.41 4.0161 0.00629 116.04 10.6071 0.2846 
A 50.05 1.151 0.010 310.25 11.1504 0.00780 517.81 49.3172 0.0000 
 16 
Supplementary Table 2.  Summary of phenotypes from individuals with hyperactivating mutations in UBE3A, 
related to Figure 7.  Phenotypes are summarized for individuals with strong (>150% of WT UBE3A activity) and 




Strong hyperactivating mutations (>150% of WT UBE3A activity) 
 
 Individual 1 Individual 2 Individual 3 Individual 4 
Individual 5 Individual 6 Individual 7 Individual 8 Individual 9 Individual 10 Individual 11 
Mutation 
(NM_130838.4) c.2359A>G c.2359A>G c.2359A>G c.2359A>G c.2176_2178delTTA c.2176_2178delTTA c.2176_2178delTTA c.2402T>A c.1561G>A c.1546C>T c.2263G>A 
Protein 
(NP_001361390.1) T787A T787A T787A T787A L726D L726D L726D L781H A521T R516W G755S 
Approximate Age 
at Investigation Adult Adolescent Adolescent Adult Adolescent Adolescent Adolescent Child N.D. Adolescent Child 
Inheritance Maternal Maternal N.D. N.D. Maternal Maternal Maternal Maternal Maternal N.D. 
Undetermined; 

































Disability Yes Yes N.D. N.D. Yes, severe 
Yes, cognitive 
ability equivalent to 
4 years of age 
Yes, has an 
individual learning 





N.D. Yes N.D. 







walking N.D. Yes N.D. 




N.D. N.D. Yes Yes, possesses limited speech No N.D. N.D. Non-verbal N.D. 
Prenatal Feeding 
Difficulties Yes N.D. N.D. N.D. G-tube dependent N.D. N.D. Yes N.D. Yes N.D. 
Behavioral 
Anomalies ASD ASD N.D. N.D. N.D. 
ADHD, lacks the 











































Anomalies N.D. N.D. N.D. N.D. N.D. 
Heterozygous for 
pathogenic mutation 





















does not carry 

















N.D. N.D. Osteoperosis 
Sibling to Individual 
5; has an 
unaffected sibling 





























Weak hyperactivating mutations (<150% of WT UBE3A activity) 
 
 Individual 12 Individual 13 Individual 14 Individual 15 Individual 16 Individual 17 
Mutation (NM_130838.4) c.2359A>G c.2359A>G c.2359A>G c.2359A>G   
Protein 
(NP_001361390.1) Q196P Q196P Q196P Q196P N692S K701I 
Approximate Age at 
Investigation Child Child Adult Child Child Adult 
Inheritance Paternal N.D. N.D. N.D. N.D. N.D. 
Seizures No No N.D. Yes, infantile-onset epilepsy 
Yes, infantile-onset 
epilepsy N.D. 
Intellectual Disability Yes N.D. N.D. N.D. N.D. N.D. 
Motor Delays Yes N.D. N.D. N.D. N.D. N.D. 
Speech Delays N.D. N.D. N.D. N.D. N.D. N.D. 
Prenatal Feeding 
Difficulties Yes N.D. N.D. N.D. N.D. N.D. 

















spasticity, club feet 
N.D. N.D. 
Other Genetic Anomalies N.D. Heterozygous VUS in KCTD7 identified No 
Heterozygous VUS in 
EHMT1, GPHN, and 
ST3GAL5 
Pathogenic variant in 




Additional Notes N.D. N.D. Identified in unaffected female N.D. N.D. 
Identified in 
unaffected female 






Supplementary Table 3.  Primers used in this study.  Lower case letters represent codons that were mutated 








































































































































STOPD sense CTGcagaacaagatcaagcagaagaagggcagaaaaaagaaagagaagatcTAAc 
STOPD antisense ccgggTTAgatcttctctttcttttttctgcccttcttctgcttgatcttgttctgCAgcatg 
Genotyping primer 
sense GAATTTTAAGTAACTTAAAGTTAATCAAC 
Genotyping primer 
antisense CTGAGATAAACTTCTGTATTTAGATAC 
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